<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-126716</identifier>
<setSpec>1139-6202</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Implementation and evaluation of a breast cancer pharmaceutical advisory programme</dc:title>
<dc:description xml:lang="en">Background: Screening is a vital process when combating cancer because it allows the early detection of the disease in individuals who have not developed symptoms yet. Aims: The aim of the present study was to show that the implementation by community pharmacists of a breast cancer screening programme coupled with risk assessment increases women's confidence in screening practices. Methods: A prospective quasi-experimental trial was conducted in five Spanish community pharmacies, at Valencia's Cardenal Herrera University and through the website www.elcancerdemama.es between June 2009 and March 2011. The participants that took part in the study were: clients of five community pharmacies interested in the programme, pharmacy and veterinary students at Cardenal Herrera University and visitors of the website. They completed questionnaires designed to collect data about risk factors for breast cancer and the implementation of measures for its early detection. In addition, pharmacists provided women with personalized information about breast cancer and how to perform breast self-examination (BSE) at the community pharmacies and at the university. A follow-up was carried out 40 days later to check the participants&#146; adherence to the programme. We evaluated pharmacists&#146; interventions in relation to breast cancer screening. Results: A total of 1,452 women were included in the study. A direct family history of breast cancer, early menarche, late menopause, obesity and overweight, null parity and hormone replacement therapy were found to be risk factors for breast cancer (p&lt;0.05). Women's confidence in performing a correct BSE improved from 16% to 82% (p&lt;0.05). 12% of the women were considered to have a high risk of developing breast cancer (p&lt;0.005). 6% of the women detected abnormalities while making a BSE. Conclusions: The pharmacists' awareness-raising campaign resulted in an improvement of self-directed behaviours across all age groups, particularly in terms of BSE (AU)</dc:description>
<dc:creator>Castillo García, E</dc:creator>
<dc:creator>Chouhayd el Ataoui, L</dc:creator>
<dc:creator>López-Castellano, A. C</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Introducción: Las pruebas de screening son vitales para combatir el cáncer, ya que permiten la detección temprana de la enfermedad en individuos que no han desarrollado síntomas. Objetivo: Demostrar que la implementación por farmacéuticos comunitarios de un programa de asesoramiento sobre cáncer de pecho, aumenta la implementación de medidas de detección precoz. Material y métodos: Se realizó un ensayo prospectivo cuasi-experimental en cinco farmacias comunitarias, en la Universidad CEU-Cardenal Herrera y a través de la página Web www.elcancerdemama.es entre Junio de 2009 y Mayo de 2011. Participaron pacientes de cinco oficinas de farmacia, estudiantes universitarias y visitantes de la página Web. Las participantes complementaron cuestionarios para recoger datos sobre factores de riesgo y sobre la implementación de medidas de detección precoz. Adicionalmente, en las oficinas de farmacia y en la universidad, los farmacéuticos proporcionaron información personalizada sobre el cáncer de pecho y sobre cómo realizar correctamente el autoexamen. A los 40 días se realizó un seguimiento para comprobar la adherencia. Evaluamos la intervención del farmacéutico en el programa de detección precoz. Resultados: Participaron 1.452 mujeres. Son factores de riesgo (p&lt;0,05) tener antecedentes familiares directos de cáncer de pecho, menarquia temprana, menopausia tardía, obesidad y sobrepeso, nuliparidad y terapia hormonal sustitutiva. La realización correcta del autoexamen mamario aumentó del 16 al 82% (p&lt;0,05). Un 12% de las mujeres tiene riesgo elevado (p&lt;0,005). Un 6% de las mujeres detectó anomalías al realizar el autoexamen. Conclusiones: La campaña de asesoramiento farmacéutico mejoró la actitud frente a la enfermedad, especialmente en términos de autoexamen mamario (AU)</dc:description>
<dc:source>Pharm. care Esp;16(4): 142-145, jul.-ago. 2014. tab, ilus</dc:source>
<dc:identifier>ibc-126716</dc:identifier>
<dc:title xml:lang="es">Implementación y evaluación de un programa de asesoramiento farmacéutico en cáncer de  pecho</dc:title>
<dc:subject>^d28599</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3189^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d28608^s22074</dc:subject>
<dc:subject>^d10794^s22045</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d14294^s22053</dc:subject>
<dc:subject>^d30225^s22074</dc:subject>
<dc:subject>^d10796^s22049</dc:subject>
<dc:subject>^d14294^s22021</dc:subject>
<dc:subject>^d10796^s22048</dc:subject>
<dc:subject>^d38340</dc:subject>
<dc:subject>^d9562^s22057</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d50249</dc:subject>
<dc:subject>^d30225^s22045</dc:subject>
<dc:type>article</dc:type>
<dc:date>201408</dc:date>
</metadata>
</record>
</ibecs-document>
